These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 34766870)
21. Potential Novel Therapies for Neurodevelopmental Diseases Targeting Oxidative Stress. Curpan AS; Luca AC; Ciobica A Oxid Med Cell Longev; 2021; 2021():6640206. PubMed ID: 34336109 [TBL] [Abstract][Full Text] [Related]
22. Characterization of schizophrenia adverse drug interactions through a network approach and drug classification. Sun J; Zhao M; Fanous AH; Zhao Z Biomed Res Int; 2013; 2013():458989. PubMed ID: 24089679 [TBL] [Abstract][Full Text] [Related]
23. A meta-analysis of peripheral blood nerve growth factor levels in patients with schizophrenia. Qin XY; Wu HT; Cao C; Loh YP; Cheng Y Mol Psychiatry; 2017 Sep; 22(9):1306-1312. PubMed ID: 28070123 [TBL] [Abstract][Full Text] [Related]
24. Role of microgliosis, oxidative stress and associated neuroinflammation in the pathogenesis of Parkinson's disease: The therapeutic role of Nrf2 activators. Jayaram S; Krishnamurthy PT Neurochem Int; 2021 May; 145():105014. PubMed ID: 33689805 [TBL] [Abstract][Full Text] [Related]
25. Allostatic load is associated with psychotic symptoms and decreases with antipsychotic treatment in patients with schizophrenia and first-episode psychosis. Berger M; Juster RP; Westphal S; Amminger GP; Bogerts B; Schiltz K; Bahn S; Steiner J; Sarnyai Z Psychoneuroendocrinology; 2018 Apr; 90():35-42. PubMed ID: 29427955 [TBL] [Abstract][Full Text] [Related]
26. Drug repurposing and emerging adjunctive treatments for schizophrenia. Bumb JM; Enning F; Leweke FM Expert Opin Pharmacother; 2015 May; 16(7):1049-67. PubMed ID: 25866122 [TBL] [Abstract][Full Text] [Related]
27. Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations. Müller N Schizophr Bull; 2018 Aug; 44(5):973-982. PubMed ID: 29648618 [TBL] [Abstract][Full Text] [Related]
28. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease. Shoaib M; Kamal MA; Rizvi SMD Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531 [TBL] [Abstract][Full Text] [Related]
29. From Clozapine to Cognitive Remediation. Quinn J; Kolla NJ Can J Psychiatry; 2017 Feb; 62(2):94-101. PubMed ID: 27335156 [TBL] [Abstract][Full Text] [Related]
30. Mitochondrial Dysfunction in Schizophrenia. Ni P; Chung S Bioessays; 2020 Jun; 42(6):e1900202. PubMed ID: 32338416 [TBL] [Abstract][Full Text] [Related]
31. The Role of Childhood Trauma in Psychosis and Schizophrenia: A Systematic Review. Inyang B; Gondal FJ; Abah GA; Minnal Dhandapani M; Manne M; Khanna M; Challa S; Kabeil AS; Mohammed L Cureus; 2022 Jan; 14(1):e21466. PubMed ID: 35223250 [TBL] [Abstract][Full Text] [Related]
32. Anti-inflammatory Strategies for Schizophrenia: A Review of Evidence for Therapeutic Applications and Drug Repurposing. Hong J; Bang M Clin Psychopharmacol Neurosci; 2020 Feb; 18(1):10-24. PubMed ID: 31958901 [TBL] [Abstract][Full Text] [Related]
33. [Effectiveness of N-acetylcysteine in the treatment of schizophrenia]. Miyake N; Miyamoto S Nihon Shinkei Seishin Yakurigaku Zasshi; 2016 Apr; 36(2):29-35. PubMed ID: 27333656 [TBL] [Abstract][Full Text] [Related]
34. Perceived stress and hair cortisol: Differences in bipolar disorder and schizophrenia. Streit F; Memic A; Hasandedić L; Rietschel L; Frank J; Lang M; Witt SH; Forstner AJ; Degenhardt F; Wüst S; Nöthen MM; Kirschbaum C; Strohmaier J; Oruc L; Rietschel M Psychoneuroendocrinology; 2016 Jul; 69():26-34. PubMed ID: 27017430 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of NDEL1 oligopeptidase activity in blood and brain in an animal model of schizophrenia: effects of psychostimulants and antipsychotics. Nani JV; Lee RS; Yonamine CM; Sant'Anna OA; Juliano MA; Gadelha A; Mari JJ; Hayashi MAF Sci Rep; 2020 Oct; 10(1):18513. PubMed ID: 33116174 [TBL] [Abstract][Full Text] [Related]
36. Doxycycline reverses cognitive impairment, neuroinflammation and oxidative imbalance induced by D-amphetamine mania model in mice: A promising drug repurposing for bipolar disorder treatment? Chaves Filho AJM; Cunha NL; Rodrigues PA; de Souza AG; Soares MV; Jucá PM; de Queiroz T; Clemente DCDS; Mottin M; Andrade CH; Peixoto CA; Macedo DS Eur Neuropsychopharmacol; 2021 Jan; 42():57-74. PubMed ID: 33191076 [TBL] [Abstract][Full Text] [Related]
37. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Segman RH; Heresco-Levy U; Finkel B; Goltser T; Shalem R; Schlafman M; Dorevitch A; Yakir A; Greenberg D; Lerner A; Lerer B Mol Psychiatry; 2001 Mar; 6(2):225-9. PubMed ID: 11317227 [TBL] [Abstract][Full Text] [Related]
38. Inflammation Subtypes and Translating Inflammation-Related Genetic Findings in Schizophrenia and Related Psychoses: A Perspective on Pathways for Treatment Stratification and Novel Therapies. Bishop JR; Zhang L; Lizano P Harv Rev Psychiatry; 2022 Jan-Feb 01; 30(1):59-70. PubMed ID: 34995036 [TBL] [Abstract][Full Text] [Related]
39. Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use. Guinart D; Moreno E; Galindo L; Cuenca-Royo A; Barrera-Conde M; Pérez EJ; Fernández-Avilés C; Correll CU; Canela EI; Casadó V; Cordomi A; Pardo L; de la Torre R; Pérez V; Robledo P Schizophr Bull; 2020 Dec; 46(6):1547-1557. PubMed ID: 32249318 [TBL] [Abstract][Full Text] [Related]
40. Characteristics of the corpus callosum in chronic schizophrenia treated with clozapine or risperidone and those never-treated. Tao B; Xiao Y; Cao H; Zhang W; Yang C; Lencer R; Gong Q; Lui S BMC Psychiatry; 2021 Oct; 21(1):538. PubMed ID: 34715831 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]